Skip to main content
Figure 2 | BMC Gastroenterology

Figure 2

From: Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

Figure 2

Survival curves between in patients receiving IFX and immunomodulators and IFX alone. (A) Cumulative remission-maintenance rates in patients receiving combination therapy (solid line) and IFX monotherapy (dotted line). Rates were similar in these two groups (73.9% at 60 months vs 56.1% at 63 months, p = 0.74). (B) Cumulative colectomy-free rates in patients receiving combination therapy (solid line) and IFX monotherapy (dotted line). These rates were also similar (91.7% at 60 months vs 66.2% at 63 months, p = 0.21).

Back to article page